Skip to content
TrialScanner

NCT01363349

Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia

Phase 2/Phase 3TerminatedBLRXLead

Registry record

Lead sponsor
BioLineRx, Ltd.
Conditions
Schizophrenia; Cognitive Effect on Schizophrenic Patients
Primary completion
Mar 2013Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT01363349 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT01363349: Phase IIb-III Study of... | TrialScanner